Last updated July 6, 2026
Key finding
LVGLS improved from -15.5 ± 3.1% to -16.6 ± 2.8%, P = 0.004.
The study evaluated the effects of ertugliflozin on cardiac function in individuals with type 2 diabetes and pre-heart failure, finding significant improvements in certain cardiac metrics.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the effects of ertugliflozin on cardiac function in individuals with type 2 diabetes and pre-heart failure, finding significant improvements in certain cardiac metrics.
These findings are clinically significant as they suggest that ertugliflozin may help improve heart function and manage diabetes in patients at risk of heart failure, potentially leading to better health outcomes. Understanding the impact of diabetes medications on heart health is crucial for optimizing treatment strategies in this vulnerable population.
Some outcomes showed no significant changes. Effectiveness of ertugliflozin remains unclear for certain metrics. Study population may limit generalizability.
Published in
Publication details and source links for this paper.
Soo L, Jae HB, Heran O, In-Chang H, Yeonyee EY, Goo-Yeong C. Ertugliflozin Improves Cardiac Function in Individuals with Type 2 Diabetes and Pre-Heart Failure. Cardiovascular Diabetology. 2024;23:373. doi:10.1186/s12933-024-02463-0
LVGLS improved from -15.5% to -16.6%, P = 0.004.
Significant reduction in HbA1c was observed.
Systolic blood pressure showed significant reduction.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Ertugliflozin and Adverse events incidence, Global longitudinal strain, HbA1c, and 9 more.
This study contributes evidence to
Primary intervention
Ertugliflozin
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
12
Evidence pairs
661
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Related evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Ertugliflozin → Adverse events incidence
Ertugliflozin → Adverse events incidence
Ertugliflozin → angiotensin-converting enzyme 2 (ACE2)
Ertugliflozin → angiotensin-converting enzyme 2 (ACE2)
Ertugliflozin → Global longitudinal strain
Ertugliflozin → Global longitudinal strain
Ertugliflozin → Incidence of proteinuria
Ertugliflozin → Incidence of proteinuria
Ertugliflozin → Left ventricular ejection fraction (LVEF)
Ertugliflozin → Left ventricular ejection fraction (LVEF)
Ertugliflozin → Left ventricular mass index
Ertugliflozin → Left ventricular mass index
Ertugliflozin → Systolic blood pressure
Ertugliflozin → Systolic blood pressure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Ertugliflozin and HbA1c, Ertugliflozin and Uric Acid Levels.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on Ertugliflozin
Contributes to Ertugliflozin evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Uric Acid Levels
Measures Uric Acid Levels as a key outcome.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Ertugliflozin may lower HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ertugliflozin may worsen uric acid or be associated with harm.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Uric Acid
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | weak negative | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ertugliflozin appears to reduce incidence of proteinuria.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Incidence of proteinuria
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Ertugliflozin appears to improve angiotensin (1-7).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
angiotensin (1-7)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
